| Project/Area Number |
18K15771
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 非アルコール性脂肪肝炎 / 肝再生 / 非アルコール性脂肪性肝炎 |
|---|
| Outline of Final Research Achievements |
In this study, we examined the effects of Epiregulin on NASH pathological progression using epiregulin gene deficient mice. In the epiregulin gene deficient mice with diet induced NASH, the degree of intrahepatic inflammation and liver fibrosis was reduced compared with WT. These results suggest that Epiregulin, a growth factor that contributes to liver regeneration during liver damage, may contribute to the progression of liver fibrosis in the process of progress of NASH disease, and we aim to further examine the detailed mechanism.
|
| Academic Significance and Societal Importance of the Research Achievements |
脂肪性肝疾患の有病率は本邦において増加しているが、未だ有効な治療薬が存在しない。こうした背景のもと、我々は肝障害時の肝再生に寄与する増殖因子であるEpiregulinが脂肪肝の肝線維化の進展に関与している可能性を明らかにした。脂肪肝における当該増殖因子の肝再生/肝線維化への関与およびその機構が明らかになれば、未だ有効な治療薬が存在しない脂肪性肝疾患の治療薬のターゲットとなり得る可能性があり、臨床的意義は大きい。
|
